The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety results of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant NSCLC.
 
David Planchard
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; MSD Oncology; Novartis; Pfizer; Roche
 
Helena Alexandra Yu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly
Research Funding - Astellas Pharma; AstraZeneca; Clovis Oncology; Incyte; Lilly
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD; Novartis; Roche
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca (Inst); Bayer; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Hansoh; Lilly; Merck Serono; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; Yuhan
 
Ki Hyeong Lee
No Relationships to Disclose
 
Pilar Garrido Lopez
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche
Speakers' Bureau - Bristol-Myers Squibb; MSD; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Roche
 
Keunchil Park
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; GlaxoSmithKline; Hanmi; Kyowa Hakko Kirin; Lilly; Novartis; Ono Pharmaceutical; Roche
Speakers' Bureau - Boehringer Ingelheim
Research Funding - AstraZeneca
 
Joo-Hang Kim
No Relationships to Disclose
 
Dae Ho Lee
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; CJ Healthcare; Health Insurance Review and Assessment Service; Korean Ministry of Food and Drug Safety; Lilly; Merck; MSD; Mundipharma; National Cancer Center; National Evidence-based healthcare Collaborating Agency; Novartis; Ono Pharmaceutical; Pfizer; Roche; Samyang; STCube Pharmaceuticals Inc.
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; CJ Healthcare; Health Insurance Review and Assessment Service; Korean Ministry of Food and Drug Safety; Lilly; Merck; MSD; Mundipharma; National Cancer Center; National Evidence-based healthcare Collaborating Agency; Novartis; Ono Pharmaceutical; Pfizer; Roche; Samyang; STCube Pharmaceuticals Inc.
 
Shuang He
Employment - Lilly; Lilly (I)
Stock and Other Ownership Interests - Lilly; Lilly (I); Lilly (I)
 
Bo H. Chao
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Luis G. Paz-Ares
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche; Takeda